NXERA PHARMA UK LIMITED

1. NXERA PHARMA UK LIMITED 2024-04-02 → present
2. HEPTARES THERAPEUTICS LIMITED 2007-06-04 → 2024-04-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors have prepared a cashflow forecast to 31 July 2026, being the going concern review period. The forecast demonstrates the Company has adequate resources to continue in operational existence for this period based upon its strong cash position at the year end. Accordingly, the Directors believe that it remains appropriate to continue to adopt the going concern basis of accounting in preparing the financial statements.”

Group structure

1. NXERA PHARMA UK LIMITED · parent
   1. Heptares Zürich AG 100% · Switzerland
   2. Nxera Pharma Ireland Limited 100% · Republic of Ireland · did not trade

Significant events

• “On 11 March 2024, the Company entered into a global collaboration and exclusive option-to-license agreement with Boehringer Ingelheim, to develop and commercialize the Company's portfolio of first-in-class GPR52 agonists, a novel GPCR target, with the intent to improve patient outcomes by simultaneously addressing positive, negative, and cognitive symptoms of schizophrenia.”
• “On 16 April 2024, the Company was notified by its partner Neurocrine Biosciences Inc, that NBI-1117568, an oral selective muscarinic M4 receptor agonist being advanced in Phase 2 clinical trials by Neurocrine for the treatment of schizophrenia and other neuropsychiatric disorders, had successfully completed a long-term preclinical toxicity program that meets US FDA requirements to allow for safe, chronic (i.e. long-term) dosing in future clinical trials. The achievement of this important safety development milestone triggered a $15 million payment to Nxera from Neurocrine.”
• “On 2 September 2024, the Company announced that it would receive a US$35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase 2 trial with NBI-1117568 in adults with schizophrenia, as announced on 28 August 2024.”
• “In the year ended 31 December 2024 there was an increase in turnover and profit before tax for the reasons stated above. Average Headcount was broadly flat. Cash at bank at the year end decreased due to £20m of cash being placed in Q4 2024 in a bank term deposit with a maturity of more than three months, requiring it to be reported on a separate line in the balance sheet.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +176.2%

  £28,310,880 → £78,197,862

• Cash

  -14.2%

  £132,186,821 → £113,413,250

• Net assets

  +4.7%

  £164,680,598 → £172,420,092

• Employees

  +1.1%

  183 → 185

• Operating profit

  +108.3%

  -£33,740,459 → £2,785,996

• Profit before tax

  +135.5%

  -£27,671,849 → £9,826,303

• Wages

  +11.4%

  £12,514,173 → £13,943,488

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers